给人服用盐酸氟奋乃静、庚酸氟奋乃静和癸酸氟奋乃静后氟奋乃静的动力学
Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.
作者信息
Curry S H, Whelpton R, de Schepper P J, Vranckx S, Schiff A A
出版信息
Br J Clin Pharmacol. 1979 Apr;7(4):325-31. doi: 10.1111/j.1365-2125.1979.tb00941.x.
Abstract
1 Fluphenazine (1,2-ethanol 14C) was administered to seven human subjects as the dihydrochloride and as the enanthate and decanoate esters. 2 The subjects had previously been treated with fluphenazine injections for at least 6 months. 3 Fluphenazine was separated from its radioactive metabolites by selective solvent extraction. Plasma concentrations were measured for up to 21 days after dosing. 4 The preparations showed differences in peak concentrations, times of the peaks and half-times of the elimination phase. The longest half-times occurred with the decanoate and the shortest with the dihydrochloride. 5 It is postulated that the differences in kinetics relate principally to the release of the compound from the site of injection. 6 There was no evidence for presence of the esters in plasma, urine or faeces.
摘要
以盐酸氟奋乃静、庚酸氟奋乃静和癸酸氟奋乃静酯的形式，将氟奋乃静（1,2 - 乙醇14C）给予7名人体受试者。
这些受试者此前接受氟奋乃静注射治疗至少6个月。
通过选择性溶剂萃取将氟奋乃静与其放射性代谢物分离。给药后长达21天测量血浆浓度。
这些制剂在峰浓度、达峰时间和消除相半衰期方面存在差异。癸酸酯的半衰期最长，盐酸盐的半衰期最短。
据推测，动力学差异主要与化合物从注射部位的释放有关。
没有证据表明血浆、尿液或粪便中存在酯类。
相似文献
1
Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.给人服用盐酸氟奋乃静、庚酸氟奋乃静和癸酸氟奋乃静后氟奋乃静的动力学
Br J Clin Pharmacol. 1979 Apr;7(4):325-31. doi: 10.1111/j.1365-2125.1979.tb00941.x.
2
Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow - release characteristics in dogs.
J Pharm Sci. 1976 Sep;65(9):1310-5. doi: 10.1002/jps.2600650912.
3
Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs.将14C-氟奋乃静庚酸酯和癸酸酯以芝麻油形式给狗注射后的释放与消除情况。
J Pharm Sci. 1976 Apr;65(4):502-507. doi: 10.1002/jps.2600650407.
4
Methods for study of fluphenazine kinetics in man.
J Pharm Pharmacol. 1976 Dec;28(12):869-73. doi: 10.1111/j.2042-7158.1976.tb04082.x.
5
Clinical pharmacokinetics of the depot antipsychotics.长效抗精神病药物的临床药代动力学
Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. doi: 10.2165/00003088-198510040-00003.
6
[Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
Encephale. 1987 Mar-Apr;13(2):83-7.
7
Depot fluphenazine enanthate and decanoate: comparative rates of release in dogs.氟奋乃静庚酸酯和癸酸酯长效注射剂：犬体内的释放速率比较
J Pharm Pharmacol. 1975 Oct;27(10):791-2. doi: 10.1111/j.2042-7158.1975.tb09407.x.
8
Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.精神分裂症患者癸酸氟奋乃静治疗期间的血浆氟奋乃静水平。
Psychopharmacology (Berl). 1985;87(1):55-8. doi: 10.1007/BF00431778.
9
Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
Am J Psychiatry. 1978 Dec;135(12):1539-42. doi: 10.1176/ajp.135.12.1539.
10
Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
Psychopharmacology (Berl). 1984;83(2):147-50. doi: 10.1007/BF00429723.
引用本文的文献
1
Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.表型药物筛选揭示代谢 GCH1/BH4 途径是 EGFR/KRAS 介导的神经性疼痛和肺癌的关键调节因子。
Sci Transl Med. 2022 Aug 31;14(660):eabj1531. doi: 10.1126/scitranslmed.abj1531.
2
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.长效注射用抗精神病药在精神分裂症中的作用：批判性评价。
Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297.
3
Improving the prediction of the brain disposition for orally administered drugs using BDDCS.利用 BDDCS 提高口服药物脑分布的预测能力。
Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. doi: 10.1016/j.addr.2011.12.008. Epub 2011 Dec 21.
4
Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil.长效抗精神病药物吸收机制的研究：芝麻油中的氟奋乃静癸酸酯。
Pharm Res. 1997 Aug;14(8):1079-84. doi: 10.1023/a:1012165731390.
5
Pharmacokinetic optimisation of the treatment of psychosis.精神病治疗的药代动力学优化
Clin Pharmacokinet. 1993 Sep;25(3):217-36. doi: 10.2165/00003088-199325030-00005.
6
Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo.在志愿者中进行的静脉注射和口服顺式（Z）-氟哌噻吨以及在Viscoleo中肌肉注射顺式（Z）-氟哌噻吨癸酸酯的药代动力学研究。
Eur J Clin Pharmacol. 1980 Oct;18(4):355-60. doi: 10.1007/BF00561395.
7
Radioimmunoassay for trifluoperazine in human plasma.人血浆中三氟拉嗪的放射免疫测定法。
Br J Clin Pharmacol. 1981 Aug;12(2):189-93. doi: 10.1111/j.1365-2125.1981.tb01199.x.
8
Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate.接受氟哌噻吨癸酸酯和顺式(Z)-氟哌噻吨治疗的慢性精神分裂症患者血清中顺式(Z)-氟哌噻吨和催乳素的浓度。
Psychopharmacology (Berl). 1982;77(1):58-65. doi: 10.1007/BF00436100.
9
Fluphenazine pharmacokinetics and therapeutic response.氟奋乃静的药代动力学与治疗反应。
Psychopharmacology (Berl). 1981;73(3):205-10. doi: 10.1007/BF00422403.
10
Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate.精神分裂症患者在使用低剂量和高剂量庚酸氟奋乃静治疗期间的血浆氟奋乃静和催乳素水平。
Psychopharmacology (Berl). 1980;71(2):131-6. doi: 10.1007/BF00434400.
本文引用的文献
1
ESTERS OF 4-(3-(2-(TRIFLUOROMETHYL)PHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEUETHANOL AS LONG-ACTING TRANQUILIZING AGENTS. SYNTHESIS OF 4-(3-(2-(TRIFLUOROMETHYL)-PHENOTHIAZIN-10-YL)PROPYL)-1-PIPERAZINEUETHANOL-ETHYL-C14 AND ITS ESTER WITH HEPTANOIC ACID. 3.4-(3-(2-(三氟甲基)吩噻嗪-10-基)丙基)-1-哌嗪乙醇酯作为长效镇静剂。4-(3-(2-(三氟甲基)吩噻嗪-10-基)丙基)-1-哌嗪乙醇-C14乙酯及其庚酸酯的合成。3.
J Med Chem. 1963 Jul;6:347-50. doi: 10.1021/jm00340a002.
2
Destruction of chlorpromazine during absorption in the rat in vivo and in vitro.大鼠体内和体外吸收过程中氯丙嗪的破坏
Br J Pharmacol. 1971 Jul;42(3):403-11. doi: 10.1111/j.1476-5381.1971.tb07125.x.
3
Excretion and biotransformation of the enanthate ester of fluphenazine- 14 C by the dog.氟奋乃静庚酸酯-14C在犬体内的排泄及生物转化
J Pharm Sci. 1971 Jun;60(6):829-33. doi: 10.1002/jps.2600600606.
4
Pharmacokinetic studies on flupenthixol and flupenthixol decanoate in man using tritium labelled compounds.使用氚标记化合物对氟哌噻吨及癸酸氟哌噻吨进行人体药代动力学研究。
Psychopharmacologia. 1972;27(1):1-10. doi: 10.1007/BF00421951.
5
Metabolic studies with long-acting compounds.长效化合物的代谢研究。
Therapie. 1973 May-Jun;28(3):441-58.
6
Determination of perphenazine and fluphenazine in whole blood by gas chromatography.
Med Lab Technol. 1973 Apr;30(2):129-32.
7
Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral chlorpromazine.癸酸氟奋乃静治疗口服氯丙嗪吸收不良的慢性住院精神分裂症患者的试验
Dis Nerv Syst. 1973 Apr-May;34(4):181-91.
8
The problem of clinical activity of long-acting neuroleptics.长效抗精神病药物的临床活性问题。
Compr Psychiatry. 1973 May-Jun;14(3):227-33. doi: 10.1016/s0010-440x(73)80015-x.
9
Double-blind trial of fluphenazine decanoate.癸酸氟奋乃静双盲试验。
Lancet. 1972 Sep 9;2(7776):543-4. doi: 10.1016/s0140-6736(72)91943-5.
10
Determination of fluphenazine in plasma by ion-pair partition chromatography.采用离子对分配色谱法测定血浆中的氟奋乃静。
Acta Pharm Suec. 1976;13(3):193-200.
Zotero 插件